ATE236154T1 - Pyrrolydin-derivate mit einer phospholipase a2 inhibierenden wirkung - Google Patents

Pyrrolydin-derivate mit einer phospholipase a2 inhibierenden wirkung

Info

Publication number
ATE236154T1
ATE236154T1 AT96925076T AT96925076T ATE236154T1 AT E236154 T1 ATE236154 T1 AT E236154T1 AT 96925076 T AT96925076 T AT 96925076T AT 96925076 T AT96925076 T AT 96925076T AT E236154 T1 ATE236154 T1 AT E236154T1
Authority
AT
Austria
Prior art keywords
pyrrolydine
phospholipase
derivatives
inhibiting effect
inhibiting
Prior art date
Application number
AT96925076T
Other languages
English (en)
Inventor
Mitsuaki Ohtani
Toshiyuki Kato
Fumihiko Watanabe
Kaoru Seno
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co filed Critical Shionogi & Co
Application granted granted Critical
Publication of ATE236154T1 publication Critical patent/ATE236154T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Detergent Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
AT96925076T 1995-07-31 1996-07-25 Pyrrolydin-derivate mit einer phospholipase a2 inhibierenden wirkung ATE236154T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP19464895 1995-07-31
PCT/JP1996/002079 WO1997005135A1 (en) 1995-07-31 1996-07-25 Pyrrolidine derivatives having phospholipase a2 inhibitory activity

Publications (1)

Publication Number Publication Date
ATE236154T1 true ATE236154T1 (de) 2003-04-15

Family

ID=16328012

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96925076T ATE236154T1 (de) 1995-07-31 1996-07-25 Pyrrolydin-derivate mit einer phospholipase a2 inhibierenden wirkung

Country Status (16)

Country Link
US (1) US5955616A (de)
EP (1) EP0848004B1 (de)
JP (1) JP3923079B2 (de)
KR (1) KR100429950B1 (de)
CN (1) CN1064682C (de)
AT (1) ATE236154T1 (de)
AU (1) AU707537B2 (de)
BR (1) BR9609744A (de)
CA (1) CA2227829A1 (de)
DE (1) DE69627164T2 (de)
DK (1) DK0848004T3 (de)
ES (1) ES2196163T3 (de)
MX (1) MX9800804A (de)
PT (1) PT848004E (de)
TR (1) TR199800157T1 (de)
WO (1) WO1997005135A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9515975D0 (en) 1995-08-04 1995-10-04 Zeneca Ltd Chemical compounds
ZA973850B (en) * 1996-05-06 1997-12-02 Reddy Research Foundation Novel antidiabetic compounds having hypolipidaemic, anti-hypertensive properties, process for their preparation and pharmaceutical compositions containing them.
AU4020897A (en) 1996-08-17 1998-03-06 Zeneca Limited 3-mercaptopyrrolidines as farnesyl protein transferase inhibitors
BR9712792A (pt) * 1996-08-28 1999-12-14 Procter & Gamble Inibidores de metaloprotease bidentada.
TW577875B (en) * 1997-01-31 2004-03-01 Shionogi & Co Pyrrolidine derivatives with inhibitory activity for phospholipase A2
EP1048659A4 (de) * 1997-11-12 2002-11-20 Inst Med Molecular Design Inc Retinoid-rezeptor-antagonisten
EE200000522A (et) * 1998-02-25 2002-02-15 Genetics Institute, Inc. Fosfolipaas A2 ensüümi inhibiitor, seda sisaldav farmatseutiline kompositsioon ning meetod fosfolipaasensüümi toime pärssimiseks
EP1109808A1 (de) * 1999-07-01 2001-06-27 Geron Corporation Substituierte indol-verbindungen und ihre verwendung für die behandlung von krebs
KR20020069183A (ko) 1999-07-26 2002-08-29 시오노기세이야쿠가부시키가이샤 트롬보포이에틴 작동성을 나타내는 의약 조성물
AU7686900A (en) * 1999-10-22 2001-05-08 Shionogi & Co., Ltd. Preventives or remedies for arrhythmia
GB9930317D0 (en) 1999-12-22 2000-02-09 Zeneca Ltd Novel compounds
GB9930318D0 (en) 1999-12-22 2000-02-09 Zeneca Ltd Novel compounds
JPWO2001072723A1 (ja) * 2000-03-28 2004-01-08 日本曹達株式会社 オキサ(チア)ゾリジン誘導体および抗炎症薬
US6768008B2 (en) * 2000-04-24 2004-07-27 Aryx Therapeutics Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
US6958355B2 (en) 2000-04-24 2005-10-25 Aryx Therapeutics, Inc. Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
EP1276730A2 (de) * 2000-04-24 2003-01-22 ARYx Therapeutics Thiazolidindion-analoga und ihre verwendung zur behandlung von diabetes
US6680387B2 (en) 2000-04-24 2004-01-20 Aryx Therapeutics Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
US6492396B2 (en) 2000-05-16 2002-12-10 Cephalon, Inc. Substituted thioacetamides
US6670358B2 (en) * 2000-05-16 2003-12-30 Cephalon, Inc. Substituted thioacetamides
WO2002006271A1 (en) * 2000-07-19 2002-01-24 F. Hoffmann-La Roche Ag Pyrimidine derivatives
AU2001294673A1 (en) 2000-09-21 2002-04-02 Aryx Therapeutics Isoxazolidine compounds useful in the treatment of diabetes, hyperlipidemia, andatherosclerosis
MXPA03006510A (es) * 2001-01-26 2003-10-15 Shionogi & Co Compuestos halogenados que muestran agonismo del receptor de trombopoyetina.
US20060047000A1 (en) * 2001-04-24 2006-03-02 Aryx Therapeutics, Inc. Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
US7189751B2 (en) * 2001-06-25 2007-03-13 Nippon Soda Co., Ltd. Oxa(thia)zolidine compounds, process for preparation thereof and anti-inflammatory agents
FR2833261B1 (fr) * 2001-12-06 2004-07-02 Yang Ji Chemical Company Ltd Nouveaux composes inhibiteurs specifiques de la phospholipase a2 secretee non pancreatique humaine du groupe ii
AUPS282602A0 (en) 2002-06-07 2002-06-27 Garvan Institute Of Medical Research Method of inhibiting cell proliferation
KR20050085115A (ko) * 2002-11-22 2005-08-29 스미스클라인 비참 코포레이션 신규 화합물
CN1926139A (zh) 2004-02-27 2007-03-07 霍夫曼-拉罗奇有限公司 稠合吡唑衍生物
DE102004014945A1 (de) * 2004-03-26 2005-10-13 Merck Patent Gmbh Prolinylderivate
US20060293374A1 (en) * 2005-06-24 2006-12-28 Beers Scott A Substituted isothiazolones
JP2012505920A (ja) * 2008-10-17 2012-03-08 エグゼリクシス, インコーポレイテッド スフィンゴシン1リン酸塩受容体拮抗薬
MX357284B (es) * 2011-05-26 2018-07-04 Univ Indiana Res & Tech Corp Compuestos de quinona para tratar enfermedades mediadas por ape1.
PL2729445T3 (pl) * 2011-07-04 2016-04-29 Rottapharm Biotech Srl Cykliczne pochodne aminowe jako antagoniści receptora EP4
WO2023283256A1 (en) 2021-07-09 2023-01-12 Aligos Therapeutics, Inc. Anti-viral compounds
US12065428B2 (en) 2021-09-17 2024-08-20 Aligos Therapeutics, Inc. Anti-viral compounds
AU2023303408A1 (en) 2022-07-06 2024-12-19 Aligos Therapeutics, Inc. Anti-viral compounds

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL57415A (en) * 1978-05-30 1984-08-31 Smith Kline French Lab Nitropyrrole compounds,process for preparing them and pharmaceutical compositions containing them
JPS6184094A (ja) * 1984-10-01 1986-04-28 日本電気株式会社 多層プリント配線板の検査用パタ−ン
JPS6212776A (ja) * 1985-07-10 1987-01-21 Taiho Yakuhin Kogyo Kk ロ−ダニン誘導体
US5130379A (en) * 1988-03-08 1992-07-14 Pfizer Inc. Hypoglycemic thiazolidinedione derivatives
GB9025987D0 (en) * 1990-11-29 1991-01-16 Ilford Ltd Merocyanine dyes
FR2680512B1 (fr) * 1991-08-20 1995-01-20 Adir Nouveaux derives de 2,4-thiazolidinedione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
AU670579B2 (en) * 1992-04-07 1996-07-25 Pfizer Inc. Indole derivatives as 5-HT1 agonists
GB9216962D0 (en) * 1992-08-11 1992-09-23 Erba Carlo Spa Therapeutically active naphthalenesulfonic-pyrrolecarboxamido derivatives
AU4444393A (en) * 1992-09-01 1994-03-10 Zeneca Limited Pyrrolidine derivatives
HU224548B1 (hu) * 1993-04-07 2005-10-28 Taiho Pharmaceutical Co. Ltd. Tiazolidinszármazékok és ezeket tartalmazó gyógyszerkészítmények, valamint eljárás előállításukra
DE4317320A1 (de) * 1993-05-25 1994-12-01 Boehringer Mannheim Gmbh Neue Thiazolidindione und diese enthaltende Arzneimittel
EP0675114A1 (de) * 1993-10-15 1995-10-04 Shionogi & Co., Ltd. Oxazolinon derivate mit inhibitorischer aktivität auf intrazelluläre phospholipase a2
JPH07138258A (ja) * 1993-11-16 1995-05-30 Taiho Yakuhin Kogyo Kk チアゾリジンジオン誘導体又はその塩
US5519134A (en) * 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers

Also Published As

Publication number Publication date
DK0848004T3 (da) 2003-07-21
EP0848004B1 (de) 2003-04-02
ES2196163T3 (es) 2003-12-16
EP0848004A4 (de) 1999-11-17
CA2227829A1 (en) 1997-02-13
DE69627164T2 (de) 2004-01-29
JP3923079B2 (ja) 2007-05-30
AU707537B2 (en) 1999-07-15
HK1016598A1 (en) 1999-11-05
KR19990036041A (ko) 1999-05-25
PT848004E (pt) 2003-07-31
TR199800157T1 (xx) 1998-06-22
WO1997005135A1 (en) 1997-02-13
EP0848004A1 (de) 1998-06-17
AU6530896A (en) 1997-02-26
DE69627164D1 (de) 2003-05-08
US5955616A (en) 1999-09-21
MX9800804A (es) 1998-07-31
CN1064682C (zh) 2001-04-18
BR9609744A (pt) 1999-03-02
CN1197458A (zh) 1998-10-28
KR100429950B1 (ko) 2004-06-16

Similar Documents

Publication Publication Date Title
DE69627164D1 (de) Pyrrolydin-derivate mit einer phospholipase a2 inhibierenden wirkung
PT705833E (pt) Derivado de dc-89
BR0014651A (pt) Inibidores de adesão de célula mediada por "alfa" l beta2
EP0976748A4 (de) Pyrrolidin-derivate die eine phospholipase-a2-hemmende wirkung haben
EP0725059A4 (de) 2,3-diaminopropionsäurederivate
PT1101755E (pt) Derivados do acido antranilico
PT1043310E (pt) Derivados de bifenilamidina
DK240084D0 (da) New beta-carboline-3-oxadiazolyl derivatives
ATE223411T1 (de) 1-methylcarbapenem-derivate
EP1026162A4 (de) Antirheumatika
FI952420A0 (fi) Glukopyranosidibentsotiofeenit
ATE237619T1 (de) Sesquiterpen-derivate mit antiviraler aktivität
DK0979822T3 (da) Fremgangsmåde til fremstilling af 2-carbamoyl-pyridiner
DE69222818D1 (de) Kondensierte Naphthyridinderivate
DE69410159D1 (de) Neue Verbindung, Leustroducsin H, ihre Herstellung und therapeutische Verwendung
ES2195309T3 (es) Derivados de tetrahidrofurano.
HUP9900736A2 (hu) Fluor-metoxi-akrilsav-származékok és kártevőirtó szerként történő alkalmazásuk
ATE159253T1 (de) 2-thiazolylpyrroleakrylate mit fungizider wirkung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0848004

Country of ref document: EP

EEIH Change in the person of patent owner
REN Ceased due to non-payment of the annual fee